{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FA&page=5",
    "query": {
      "intervention": "FA",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 112,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FA&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FA&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T01:41:27.263Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01539473",
      "title": "A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TR-701 FA with Tyramine",
          "type": "DRUG"
        },
        {
          "name": "Placebo-controlled withTyramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-02",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-03",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539473"
    },
    {
      "nct_id": "NCT05001282",
      "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Endometrial Cancer",
        "Ovary Cancer",
        "Ovary Neoplasm",
        "Ovary Disease",
        "Ovary Metastasis",
        "Ovarian Diseases",
        "Ovarian Cancer Stage",
        "Ovarian Epithelial Cancer",
        "Ovarian Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Neoplasm Epithelial",
        "Ovarian Cancer Recurrent",
        "Endometrial Diseases",
        "Endometrial Adenocarcinoma",
        "Endometrial Carcinosarcoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrioid Adenocarcinoma",
        "Endometrial Neoplasms",
        "Endometrial Cancer Recurrent",
        "Endometrioid Tumor",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "ELU001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elucida Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2021-09-13",
      "completion_date": "2024-06-07",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001282"
    },
    {
      "nct_id": "NCT02017704",
      "title": "Chemoradiation or Brachytherapy for Rectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Endo-HDR (if randomized to this arm)",
          "type": "RADIATION"
        },
        {
          "name": "capecitabine and IMRT (if randomized to this arm)",
          "type": "DRUG"
        },
        {
          "name": "IMRT (intensity modulated radiation therapy)",
          "type": "RADIATION"
        },
        {
          "name": "FOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-06-12",
      "completion_date": "2023-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02017704"
    },
    {
      "nct_id": "NCT02748512",
      "title": "Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "FAI Insert administered using the Mk II inserter",
          "type": "DRUG"
        },
        {
          "name": "FAI Insert administered using the Mk I inserter",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2016-02-23",
      "completion_date": "2017-08-17",
      "has_results": true,
      "last_update_posted_date": "2020-05-01",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 6,
      "location_summary": "Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Ladson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748512"
    },
    {
      "nct_id": "NCT00056186",
      "title": "Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Friedreich Ataxia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2003-03",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056186"
    },
    {
      "nct_id": "NCT07869654",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Friedreich Ataxia",
        "Cardiomyopathies",
        "Central Nervous System Diseases",
        "Neuromuscular Diseases",
        "Mitochondrial Diseases",
        "Mitochondrial Dysfunction",
        "Genetic Disease"
      ],
      "interventions": [
        {
          "name": "ATI-105",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adjuvia Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-10-26",
      "completion_date": "2027-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07869654"
    },
    {
      "nct_id": "NCT05850520",
      "title": "A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema Secondary to Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        },
        {
          "name": "Fluorescein",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 892,
      "start_date": "2023-05-15",
      "completion_date": "2025-05-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 53,
      "location_summary": "Fullerton, California • Long Beach, California • Mountain View, California + 48 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05850520"
    },
    {
      "nct_id": "NCT07681713",
      "title": "Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "Vatiquinone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "7 Years to 21 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-08-15",
      "completion_date": "2029-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07681713"
    },
    {
      "nct_id": "NCT02928224",
      "title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "BRAF V600E-mutant Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Folinic Acid",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 702,
      "start_date": "2016-10-13",
      "completion_date": "2022-11-10",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 90,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02928224"
    },
    {
      "nct_id": "NCT07408583",
      "title": "Prenatal Transplantation for Fetuses With Fanconi Anemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fanconi Anemia",
        "Anemia, Hypoplastic, Congenital",
        "Congenital Bone Marrow Failure Syndromes",
        "Bone Marrow Failure Disorders",
        "Genetic Diseases, Inborn",
        "Congenital, Hereditary, and Neonatal Diseases and Abnormalities",
        "DNA Repair-Deficiency Disorders",
        "Cancer Predisposition Syndrome"
      ],
      "interventions": [
        {
          "name": "IUHSCT for FA-affected fetuses",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Agnieszka Czechowicz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2028-01",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-21T01:41:27.263Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Stanford, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07408583"
    }
  ]
}